other exon skipping candidates — IND submission
2026
Expect to submit multiple CTAs for other exon skipping candidates in 2026Source filing
WVE biotech catalysts & pipeline
WAVE LIFE SCIENCES INC · Data as of 2026-10-27
Upcoming catalysts
WVE-N531 — NDA/BLA submission
in 2026
WVE-N531: Wave remains on track to file a New Drug Application (NDA) in 2026 to support accelerated approval of WVE-N531 with monthly dosing.Source filing
WVE-006 — FDA meeting
Late 2026
FDA meeting scheduled for end of summer 2026 on potential accelerated approval pathway for WVE-006 (GalNAc-RNA editing); data from RestorAATion-2 trial support differentiated therapeutic approach for both lung and liver manifestations of AATDSource filing
WVE-006 — Clinical data readout
Q4 2026
Wave expects to share data from the 600 mg (monthly) multidose cohort in the fourth quarter of 2026.Source filing
WVE-007 — Clinical data readout
Q4 2026
Wave expects to share data from the Phase 1 600 mg SAD cohort in the fourth quarter of 2026.Source filing
WVE-008 — IND submission
Q4 2026
A clinical trial application (CTA) filing for WVE-008 is on track for the fourth quarter of 2026.Source filing